top of page


  1. Khoury JD, Solary E, Abla O,  et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 2022; 36: 1703–1719.

  2. Brockow K. Epidemiology, prognosis, and risk factors in mastocytosis. Immunology and allergy clinics of North America. 2014;34(2):283-95.

  3. Wolff K, Komar M, Petzelbauer P. Clinical and histopathological aspects of cutaneous mastocytosis. Leukemia research. 2001;25(7):519-28.

  4. Keklik Karadağ F, Davulcu EA, Soyer N. Sistemik  mastositozis. Vural F, editör. Kronik Miyeloid Lösemi ve Kronik MiyeloproliferatifHastalıklar. 1. Baskı. Ankara: Türkiye Klinikleri; 2021. p.97-103.

  5. Radia DH, Green A, Oni C, Moonim M. The clinical and pathological panoply of systemic mastocytosis . Br J Haematol. 2020; 188(5):623-640.

  6. El Hussein S, Chifotides HT, Khoury JD, et al. Systemic Mastocytosis and Other Entities Involving Mast Cells: A Practical Review and Update. Cancers (Basel). 2022 Jul 17;14(14):3474.

  7. Sotlar K, Horny HP, Simonitsch I, et al. CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. The American journal of surgical pathology. 2004;28(10):1319-25.

  8. Pardanani A. Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management.Am J Hematol. 2021;96(4):508-525.

bottom of page